Immunology

Therapies for autoimmune and inflammatory diseases, including biologics and small molecules targeting immune pathways.

Companies

Pipeline Drugs

1853

Key People

2264

Immunology Pipeline (1853 drugs)

Preclinical: 267Commercial: 188Phase 1: 140Phase 3: 136Pre-clinical: 131Approved: 116Phase 2: 108Discovery: 68Phase 1/2: 60Phase III: 43Marketed: 41Development: 31Research: 27Approved/Commercial: 16Phase 1b: 14Phase 2b: 14Launched: 14Service: 13Discovery/Preclinical: 12Not Specified: 11Research-Use Only: 10Not Disclosed: 10Clinical: 9Phase 2a: 9Regulatory Review: 8Phase I/II: 8Research/Pre-clinical: 8N/A: 8Phase 2/3: 6IND-Enabling: 6Validated: 6Phase II: 6Early Phase: 6Pre‑clinical: 5Phase 1b/2a: 5Pre-clinical/Development: 5Development/Commercial: 5Service Offering: 5Process Scale‑up: 4Clinical Trial: 4Filed: 4NDA Submitted: 4Phase I: 4Not specified: 4Commercial Model: 4Clinical Development: 4Phase 1b/2: 4Preclinical/Phase 1: 3BLA Submitted: 3Commercial/Development: 3LDT: 3Phase 3 / Registration: 3Unknown: 3Pre-Clinical: 3Discovery/Pre-clinical: 3Lead Generation/Optimization: 3Preclinical through Commercial: 3Clinical POC: 3Approved / Lifecycle: 3ANDA Filed/Approved: 3Clinical Trials: 3Early Preclinical: 2Various: 2Approved/Under Review: 2Research Use Only: 2Early Discovery: 2Preclinical Research: 2Commercialization: 2Phase IIa: 2Commercial Service: 2Validation: 2Undisclosed: 2Approval: 2Research/Assay Development: 2Non-clinical: 2Preclinical/Discovery: 2Preclinical/Technical Development: 2Lead Optimization: 2Discovery/Research: 2Lead ID: 2Discovery/Optimization: 2Preclinical/Research: 2Clinical (Phase not specified): 2Registration: 2Late-stage Development: 2Pre-clinical/Research: 2Approved / Phase III: 2Phase III / Marketed: 2Approved / Phase 3: 2Early Development: 2Preclinical/Phase I: 2Approved (CE Mark): 1Approved (EUA): 1IND Filed: 1Approved / Marketed: 1Phase 1/2 (Special Access Program): 1Pipeline: 1Post-approval study: 1Clinical (specific phase undisclosed): 1Clinical stage (specific phases not disclosed): 1Under Regulatory Review: 1Approved (Japan): 1Commercial/Validated: 1Research & Development: 1Validated/Commercial: 1Cleared: 1Clinical trial: 1Advanced Development: 1Platform: 1Preclinical/Translational: 1Clinical Research: 1All Phases: 1Pre-clinical to Phase 3 (Bioequivalence): 1Research/Development: 1Development (with GenScript): 1Approved/Prototype: 1Research/Preclinical: 1Expanded Access: 1Clinical Stage: 1Exploratory/Pre-clinical: 1Not Disclosed (Likely Pre-clinical/Early Clinical): 1Commercial Development: 1Commercial Enhancement: 1Phase 3 / Marketed: 1Not Specified (Preclinical-Phase 2): 1Pre-clinical (inferred): 1Pre-clinical/Discovery: 1Clinical (Phase unspecified): 1Pre-commercial: 1Discovery Lead Optimization: 1Development Candidate (DC) expected 2026: 1Development Candidate (DC) expected 2027: 1Exploratory: 1LDT/Service: 1Proof of concept: 1Phase not specified (Data presented): 1Open-Label Extension: 1Acquisition announced: 1Hit to Lead: 1Late-stage (Animal Rule): 1Pre-clinical / Phase 1 (implied): 1Not Applicable (Device): 1Clinical trials (phase unspecified): 1Pre-clinical/Clinical: 1Phase 1/Phase 2: 1Commercial / Line Extension: 1Development & Validation: 1Lead Optimisation: 1Research/Validation: 1Commercial & Development: 1Completed R&D: 1Hit-to-Lead: 1Validated/Clinical Use: 1Development/Service: 1Business Development: 1Research/Concept: 1Range from Pre-clinical to Late-stage: 1Various (Pre-clinical to Clinical): 1Clinical-stage (Phase not specified): 1N/A (Early Access Program): 1N/A (Commercial/Expanded Access): 1N/A (Donation/Distribution Program): 1Pre-clinical/Clinical Study: 1Discovery to Pre-clinical Candidate: 1Phase 3/Registration: 1Pre-clinical / CTA Cleared: 1ANDA Development / Commercial: 1Development/Early Access: 1Pre-clinical/Clinically Ready: 1IND Enabling: 1Not Applicable (Service Provider): 1Phase 2 (next-gen): 1Pre-clinical development: 1Phase 4: 1Pivotal: 1Phase 1 Completed: 1IND filed: 1Registration/Clinical: 1Proof of Concept: 1Investigator‑initiated trial: 1Pre‑clinical / IND filing: 1Phase 1/2 completed, Phase 2b upcoming: 1Phase 1/2a: 1NDA filing: 1Launched/Phase 3: 1Pre-registration: 1Preclinical to Phase 2: 1Filed/Approved: 1Development/Filed: 1Phase 2b/3: 1Phase II/III: 1Clinical/Commercial: 1NDA Resubmitted: 1Marketed/Development: 1Marketed / Phase 4: 1Marketed / Phase 2/3: 1Regulatory (EU): 1Approved (EU): 1Phase 1-3: 1Research to Phase 3: 1Marketed/Phase 3: 1Preclinical / Phase 1 (planned): 1NDA Filed: 1Pre-launch: 1Discovery/Development: 1Phase 1a/1b: 1Phase not specified (Class 1 New Drug): 1Not specified (API/Formulation): 1sNDA Submitted: 1Phase 3 Completed: 1Phase 1/2 (Inferred): 1Phase 1 (Inferred): 1Phase 1/1b: 1Partnered / Discovery: 1Discovery to Clinical: 1Preclinical to Commercial: 1Phase 2/Phase 3: 1BLA Submission: 1Launch Preparation: 1Phase I to Phase III: 1FDA 510(k) Submission: 1Research Use: 1Clinical Research / LDT: 1Phase 2 Ready: 1Phase 3-ready: 1IND Approved: 1Not Specified (Likely Clinical): 1Clinical Trial (phase not specified): 1Marketed (EUA): 1Phase 1/2 / Pivotal Path: 1Phase 1 (Planned): 1

Drug	Company	Indication	Phase	Status
Herceptin (Trastuzumab) Biosimilar	NeuClone	HER2‑positive Breast Cancer	Phase 1	Active
Stelara (Ustekinumab) Biosimilar	NeuClone	Psoriasis / Crohn's Disease	Phase 1	Active
Perjeta (Pertuzumab) Biosimilar	NeuClone	HER2‑positive Breast Cancer	Process Scale‑up	Active
Opdivo (Nivolumab) Biosimilar	NeuClone	Various Cancers (PD‑1 inhibitor)	Process Scale‑up	Active
Keytruda (Pembrolizumab) Biosimilar	NeuClone	Various Cancers (PD‑1 inhibitor)	Process Scale‑up	Active
Prolia/XGEVA (Denosumab) Biosimilar	NeuClone	Bone Metastases / Osteoporosis	Process Scale‑up	Active
Humira (Adalimumab) Biosimilar	NeuClone	Autoimmune Diseases	Early Preclinical	Active
Synagis (Palivizumab) Biosimilar	NeuClone	RSV Prophylaxis	Early Preclinical	Active
RASTRUM™ 3D Pancreatic Cancer Model	Inventia Life Science	Pancreatic D	Pre‑clinical	Active
RASTRUM™ 3D Alzheimer’s Disease Model	Inventia Life Science	Alzheimer’s disease	Pre‑clinical	Active
RASTRUM™ 3D Tumor‑Immune Co‑culture Platform	Inventia Life Science	Immuno‑oncology	Pre‑clinical	Active
DVI-001	Divamics	Inflammatory Bowel Disease	Preclinical	Approaching PCC selection
DVI-002	Divamics	Inflammatory Bowel Disease	Preclinical	Lead optimization
DVI-003	Divamics	Diabetes and Obesity	Preclinical	Early-stage optimization
DVI-004	Divamics	Metabolic Disease	Preclinical	Recently disclosed
Takp-119	Akaal Pharma	Atopic dermatitis (pruritus)	Phase 2	Active
Oakp-11	Akaal Pharma	Autoimmune diseases; neuropathic pain	Phase 1	Active
Sanoosa‑001	Sanoosa	Chronic Inflammatory Disease	Preclinical	Active
Sanoosa‑002	Sanoosa	Solid Tumor Oncology	Preclinical	Active
Sanoosa‑003	Sanoosa	COVID‑19 Antiviral	Preclinical	Active
CAR‑iNK‑OvCa	Cartherics	Ovarian Cancer	Preclinical	Active
CAR‑iNK‑TNBC	Cartherics	Triple‑Negative Breast Cancer	Preclinical	Active
EV‑Endo	Cartherics	Endometriosis	Preclinical	Active
UDAB-M™ Platform Candidates	Biomissile	Various diseases with unmet needs	Preclinical	Active
Mimotopes-001	Mimotopes	Solid Tumours (NY-ESO-1 positive)	Phase 1/2	Active
Mimotopes-002	Mimotopes	Non‑Small‑Cell Lung Cancer (PD-L1)	Phase 1	Active
Mimotopes-003	Mimotopes	Multiple Sclerosis	Preclinical	Active
Mimotopes-004	Mimotopes	Influenza	Preclinical	Active
Turq-101	Turquoise Biotechnologies	Inflammatory Bowel Disease	Preclinical	Active
Turq-102	Turquoise Biotechnologies	Colon Cancer	Preclinical	Active
LW-02 Immunopheresis	Immunicom	Advanced, refractory triple-negative breast cancer (TNBC)	Approved (CE Mark)	Active
AC-201	Accro Bioscience	Moderate-to-Severe Plaque Psoriasis	Phase 2	Completed (China); partnered with Fosun Pharma for Greater China
AC-101	Accro Bioscience	Ulcerative Colitis / Inflammatory Bowel Disease	Phase 1b	Active; FDA clearance for Phase II MRCT
AC-003	Accro Bioscience	Acute Graft-Versus-Host Disease (aGVHD)	Phase 1b	Active; FDA Orphan Drug Designation
ARCoV	Abogen	COVID-19	Approved (EUA)	Commercial/Authorized
Undisclosed Candidate 1	Abogen	Oncology/Autoimmune	Clinical	Active
Undisclosed Candidate 2	Abogen	Oncology/Autoimmune	Clinical	Active
RLS-2202	Patrys	Acute Delirium	Phase 1	Active
PAT-DX1	Patrys	Vasculitis / Inflammatory Disease	Preclinical	Active
PAT-DX3	Patrys	Vasculitis / Inflammatory Disease	Preclinical	Active
Deoxymab Oncology Candidate	Patrys	Solid Tumor Cancer	Preclinical	Active
GEMINI	Revelation Biosciences	Prevention of Acute Kidney Injury (AKI) following cardiac surgery	Phase 2	Active
INNA-051	ENA Respiratory	Prophylaxis against viral respiratory infections (e.g., SARS‑CoV‑2, influenza, rhinovirus)	Phase 2	Active
PRG1801 (Anti-BCMA CAR-T)	Pregene Biopharma	Multiple Myeloma	Phase 1	Active
CAR-NK Therapy	Pregene Biopharma	Multiple Myeloma	Phase 1	Active (recruiting)
BEAT‑CAR‑T-001	Currus Biologics	Solid Tumours (breast, colon, pancreas, prostate)	Preclinical	Active
AXA-042	Axelia Oncology	Solid Tumors (checkpoint‑insensitive)	Phase 1	Active
Meta10-19	Leman Biotech	Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 1/2	Active (FDA IND cleared March 2026)
Meta10-BCMA CAR-T	Leman Biotech	Relapsed/Refractory Plasma Cell Neoplasms	Phase 1	Active (Investigator-Initiated Trial)
Meta10-TILs	Leman Biotech	Advanced Solid Tumors	Phase 1	Active (Investigator-Initiated Trial)